Data Presented Today at American Heart Association Scientific Sessions Shows iRhythm Technologies' ZIO® Patch Key to Determining True Atrial Fibrillation
Burden
Chicago, IL– November 17, 2014 – iRhythm Technologies, Inc.announced today that study results presented during the American Heart Association (AHA)
Scientific Sessions showed an association between a high burden of atrial fibrillation (AFib) and lower cognitive function, specifically executive and
verbal function.Previous studies have shown a relationship between AFib,cognitive decline and increased risk of dementia. However, this study, which was
led by researchers at the University of Minnesota, demonstrates for the first time acorrelationbetween high AFib burden - the percent of time a person has
AFib - and cognition.
The study, "Higher Burden of Atrial Fibrillation is Independently Associated with Lower Cognitive Function: The Atherosclerosis Risk in Communities (ARIC)
Study (Abstract # 12946)", analyzed 325 participants usingiRhythm Technologies' ZIO®Patch, a non-invasive, leadless, cardiac monitor that can record and
store up to two weeks of ECG data.The study found that compared with participants who did not have AFib, participants with AFib burden of 100%,had lower
Animal Naming (AN) and Digit Span Backwards (DSB) scores. The ARIC study is funded by the National Institutes of Health.
"Continuous long-term cardiac monitoring is essential to detect AFib, which may occur infrequently and often has no symptoms," said lead author Dr. Lin Yee
Chen, M.D., M.S., Assistant Professor, Cardiovascular Division, Department of Medicine, University of Minnesota. "In order to determine AFib burden, and
not just the presence or absence of AFib, continuous monitoring and analysis of all of the data is required. We used the ZIO Service,which analyzes the
beat-to-beat data in its entirety,which enabled us to identify a subpopulation of patients with lower AFib burden who otherwise would not have been
detected."
The ZIO® Serviceis the first long-term continuous monitoring service that is supported by extensive clinical data with peer-reviewed publications, and
enables diagnosis earlier in the clinical pathway to improve patient outcomes.
"Advances in continuous heart monitoring solutions have enabled a greater clinical understanding of AFib and other arrhythmias compared to standard
ambulatory electrocardiographic monitoring," said Judy Lenane, RN, MHA, executive vice president and chief clinical officer of iRhythm Technologies,
Inc."This new data is significant as it shows for the first time that a patient with persistentatrial fibrillation, as detected through long-term
continuous ECG monitoring with a device such as the ZIO®Patch,ismore likely to have lower cognitive function."
iRhythm Technologies, Inc. was also included in two other poster presentations, including the study, "Non-sustained Ventricular Tachycardia (NSVT) is
Independently Associated with Lower Cognitive Executive Function: ARICStudy (Poster #12962)"(presented on November 17 morning) and "Incidence and Timing of
High-Risk Arrhythmias with Long-Term Continuous Ambulatory Electrocardiographic Monitoring (Poster #16305)," which will be presented on November 18.
The ZIO Service, comprised of the ZIO Patch, proprietary algorithms and the ZIO Report, is proven in multiple, peer-reviewed published studies to produce a higher diagnostic yield and to change patient management, compared to traditional ambulatory electrocardiogram (ECG) monitoring. The ZIO Patch is a noninvasive, water-resistant monitor that is easy to use and discrete to wear, and is worn for up to 14 days, prompting high patient compliance and a higher diagnostic yield. Proprietary algorithms analyze the vast amounts of captured heart beat data and a concise report is provided to the patient's physician. Since its commercial launch in 2011, the ZIO Service has been used with more than 300,000 patients at nearly 800 institutions nationwide. The ZIO Service is covered for most Medicare patients and by leading private payers nationwide, representing more than 170 million covered lives.
iRhythm is a privately held digital healthcare company that aspires to be the world leader in cardiac arrhythmia information. iRhythm develops and
commercializes FDA-cleared solutions that integrate consumer-friendly biosensor technology, vast patient data, powerful analytics and medical expertise.
Its flagship solution, the ZIO Service, offers a proven approach to long-term continuous monitoring that enables diagnosis earlier in the clinical pathway
to improve patient outcomes and reduce healthcare costs. For more information,
please visit www.irhythmtech.com.
Media Contact
Amanda Breeding
Amanda.breeding@edelman.com
415-229-7649